[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-001", "question": "A 4-year-old boy presents with recurrent bacterial infections since infancy, including pneumonia and otitis media. Laboratory evaluation reveals absent CD19+ B cells, normal T cell numbers with preserved proliferation to mitogens, and undetectable serum immunoglobulins. Genetic testing identifies a mutation in a cytoplasmic tyrosine kinase essential for B cell development. His 2-year-old brother is asymptomatic but has the same mutation. Which of the following best explains the brother's lack of clinical manifestations?", "options": ["Residual maternal IgG providing passive immunity", "Somatic mosaicism with partial gene function restoration", "Compensatory upregulation of alternative signaling pathways", "X-chromosome inactivation favoring the wild-type allele", "Presence of a hypomorphic rather than null mutation"], "answer": "A", "answer_index": 0, "explanation": "This case describes X-linked agammaglobulinemia (XLA) due to BTK mutation. At age 2, the asymptomatic brother may still have residual transplacentally acquired maternal IgG, which typically wanes by 6-9 months but can persist longer in some cases, providing temporary protection. X-chromosome inactivation is irrelevant as this is an X-linked recessive condition affecting males who have only one X chromosome. Somatic mosaicism and hypomorphic mutations would show some B cell development, which is absent here.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: The 4-year-old proband has recurrent bacterial infections since infancy, absent CD19+ B cells, normal T cells, undetectable serum immunoglobulins, and a BTK mutation consistent with X-linked agammaglobulinemia (XLA); the 2-year-old brother shares the same mutation but is asymptomatic, with no laboratory details provided for him. These clues point to XLA in both, with the brother's lack of symptoms best explained by residual maternal IgG providing temporary passive immunity, as symptoms typically emerge after it wanes.\\nMain logical issue(s), if any: None; the stem supports A as the unique best option, eliminating others (e.g., D irrelevant in males, E contradicted by proband's null phenotype despite same mutation, B and C less likely/not standard).\\nMain medical accuracy issue(s), if any: Mostly aligns with standard XLA knowledge (BTK mutation causing B cell absence, delayed symptoms post-maternal IgG waning), but attributes protection at age 2 to residual maternal IgG, which typically wanes by 6-12 months and is negligible by 24 months—potentially misleading, as later asymptomatic periods more often due to limited pathogen exposure.\\nMinimal fix: Change '2-year-old brother' to '9-month-old brother' in the stem to match typical maternal IgG persistence timeline.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: The 4-year-old proband has recurrent bacterial infections since infancy, absent CD19+ B cells, normal T cells, undetectable serum immunoglobulins, and a BTK mutation consistent with X-linked agammaglobulinemia (XLA); the 2-year-old brother shares the same mutation but is asymptomatic, with no laboratory details provided for him. These clues point to XLA in both, with the brother's lack of symptoms best explained by residual maternal IgG providing temporary passive immunity, as symptoms typically emerge after it wanes.\nMain logical issue(s), if any: None; the stem supports A as the unique best option, eliminating others (e.g., D irrelevant in males, E contradicted by proband's null phenotype despite same mutation, B and C less likely/not standard).\nMain medical accuracy issue(s), if any: Mostly aligns with standard XLA knowledge (BTK mutation causing B cell absence, delayed symptoms post-maternal IgG waning), but attributes protection at age 2 to residual maternal IgG, which typically wanes by 6-12 months and is negligible by 24 months—potentially misleading, as later asymptomatic periods more often due to limited pathogen exposure.\nMinimal fix: Change '2-year-old brother' to '9-month-old brother' in the stem to match typical maternal IgG persistence timeline.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-002", "question": "A 58-year-old woman with metastatic melanoma receiving combination ipilimumab and nivolumab develops acute onset confusion, fever to 39.2°C, and neck stiffness on day 21 of treatment. CSF analysis shows 180 WBC/μL (92% lymphocytes), protein 156 mg/dL, glucose 52 mg/dL (serum 98 mg/dL), and negative Gram stain. MRI brain shows leptomeningeal enhancement. CSF cytology and flow cytometry are negative for malignant cells. Which additional CSF finding would most strongly support the diagnosis of immune checkpoint inhibitor-induced aseptic meningitis over infectious or neoplastic etiologies?", "options": ["Elevated CSF adenosine deaminase level", "Presence of oligoclonal bands with matched serum bands", "Markedly elevated CSF IL-17 levels", "CD4+/CD8+ T cell ratio greater than 4:1 with activated phenotype", "Elevated CSF beta-2 microglobulin"], "answer": "D", "answer_index": 3, "explanation": "Immune checkpoint inhibitor-induced aseptic meningitis characteristically shows a CD4+ predominant lymphocytic pleocytosis with activated T cell phenotype (expressing HLA-DR, CD69), reflecting the mechanism of enhanced T cell activation. Elevated ADA suggests tuberculosis; oligoclonal bands suggest MS or infectious processes; elevated IL-17 is nonspecific; beta-2 microglobulin elevation occurs in lymphomatous meningitis. The CD4+/CD8+ ratio with activation markers specifically reflects the immunologic mechanism of checkpoint inhibitor toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic melanoma on combination ipilimumab and nivolumab, acute confusion, fever, neck stiffness on day 21, CSF with lymphocytic pleocytosis (180 WBC/μL, 92% lymphocytes), elevated protein (156 mg/dL), normal glucose (52 mg/dL vs. serum 98), negative Gram stain, leptomeningeal enhancement on MRI, and negative cytology/flow for malignancy. These suggest aseptic meningitis, with the question seeking a CSF finding to favor immune checkpoint inhibitor (ICI)-induced over infectious/neoplastic causes. The keyed answer D (CD4+/CD8+ T cell ratio >4:1 with activated phenotype) fits due to ICI mechanism enhancing T-cell activation, often CD4-predominant in neurotoxicities. Alternatives are inferior: A (elevated ADA) supports TB; B (oligoclonal bands with matched serum) suggests MS or infection; C (elevated IL-17) is nonspecific; E (elevated beta-2 microglobulin) indicates lymphomatous involvement. No main logical issues; stem allows discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with current understanding of ICI-related aseptic meningitis featuring activated CD4+ T-cell predominance per oncology guidelines (e.g., ASCO). Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic melanoma on combination ipilimumab and nivolumab, acute confusion, fever, neck stiffness on day 21, CSF with lymphocytic pleocytosis (180 WBC/μL, 92% lymphocytes), elevated protein (156 mg/dL), normal glucose (52 mg/dL vs. serum 98), negative Gram stain, leptomeningeal enhancement on MRI, and negative cytology/flow for malignancy. These suggest aseptic meningitis, with the question seeking a CSF finding to favor immune checkpoint inhibitor (ICI)-induced over infectious/neoplastic causes. The keyed answer D (CD4+/CD8+ T cell ratio >4:1 with activated phenotype) fits due to ICI mechanism enhancing T-cell activation, often CD4-predominant in neurotoxicities. Alternatives are inferior: A (elevated ADA) supports TB; B (oligoclonal bands with matched serum) suggests MS or infection; C (elevated IL-17) is nonspecific; E (elevated beta-2 microglobulin) indicates lymphomatous involvement. No main logical issues; stem allows discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with current understanding of ICI-related aseptic meningitis featuring activated CD4+ T-cell predominance per oncology guidelines (e.g., ASCO). Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-003", "question": "A 6-month-old infant presents with progressive hypotonia, poor feeding, and developmental regression over 2 weeks. Parents report a recent upper respiratory infection. Examination reveals absent deep tendon reflexes, tongue fasciculations, and paradoxical breathing. EMG shows fibrillation potentials and reduced motor unit recruitment. Genetic testing for SMN1 deletions is negative. CSF protein is markedly elevated at 280 mg/dL. Which of the following is the most likely diagnosis?", "options": ["Infantile-onset Pompe disease", "Acute motor axonal neuropathy variant of Guillain-Barré syndrome", "Spinal muscular atrophy type 1 with atypical genetics", "Infantile botulism", "Cytomegalovirus-associated polyradiculopathy"], "answer": "B", "answer_index": 1, "explanation": "The combination of acute/subacute onset following infection, areflexia, tongue fasciculations (cranial nerve involvement), paradoxical breathing, EMG showing denervation, and markedly elevated CSF protein with albuminocytologic dissociation strongly suggests acute motor axonal neuropathy (AMAN), a GBS variant. SMA type 1 would have positive SMN1 testing in >95% of cases and insidious onset. Infantile botulism shows decremental response on repetitive stimulation and normal CSF. Pompe disease shows myopathic EMG changes. CMV polyradiculopathy typically occurs in immunocompromised patients.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute/subacute onset post-URI, progressive hypotonia with developmental regression, absent DTRs, tongue fasciculations indicating bulbar involvement, paradoxical breathing suggesting diaphragmatic weakness, EMG with fibrillation and reduced recruitment consistent with denervation, negative SMN1 ruling out typical SMA, and markedly elevated CSF protein (280 mg/dL) implying albuminocytologic dissociation. These collectively point to a post-infectious acute neuropathy like AMAN variant of GBS (option B), which fits the clinical picture without requiring unstated assumptions. Main logical issues: none; the vignette provides sufficient discriminating details to identify B as the single best answer, with no contradictions or multiple defensible options. Alternatives are inferior: A (Pompe) shows myopathic EMG, not denervation or high CSF; C (atypical SMA) typically insidious without post-infectious trigger; D (botulism) has normal CSF and specific EMG findings absent here; E (CMV) usually in immunocompromised hosts, not matching this immunocompetent infant. Main medical accuracy issues: none; aligns with standard guidelines on GBS variants in pediatrics, including post-infectious AMAN with cranial nerve involvement and CSF findings. Minimal fix: none needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute/subacute onset post-URI, progressive hypotonia with developmental regression, absent DTRs, tongue fasciculations indicating bulbar involvement, paradoxical breathing suggesting diaphragmatic weakness, EMG with fibrillation and reduced recruitment consistent with denervation, negative SMN1 ruling out typical SMA, and markedly elevated CSF protein (280 mg/dL) implying albuminocytologic dissociation. These collectively point to a post-infectious acute neuropathy like AMAN variant of GBS (option B), which fits the clinical picture without requiring unstated assumptions. Main logical issues: none; the vignette provides sufficient discriminating details to identify B as the single best answer, with no contradictions or multiple defensible options. Alternatives are inferior: A (Pompe) shows myopathic EMG, not denervation or high CSF; C (atypical SMA) typically insidious without post-infectious trigger; D (botulism) has normal CSF and specific EMG findings absent here; E (CMV) usually in immunocompromised hosts, not matching this immunocompetent infant. Main medical accuracy issues: none; aligns with standard guidelines on GBS variants in pediatrics, including post-infectious AMAN with cranial nerve involvement and CSF findings. Minimal fix: none needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-004", "question": "A 45-year-old man with acute myeloid leukemia undergoes allogeneic hematopoietic stem cell transplantation. On day +14, he develops fever, hypoxemia, and diffuse pulmonary infiltrates. Bronchoalveolar lavage shows hemorrhagic return with progressively bloodier aliquots. DAD is seen on transbronchial biopsy. Galactomannan, beta-D-glucan, and respiratory viral panel are negative. He is on tacrolimus with therapeutic levels. Which of the following findings would most strongly support a diagnosis of diffuse alveolar hemorrhage due to transplant-associated thrombotic microangiopathy rather than idiopathic pneumonia syndrome?", "options": ["Elevated serum lactate dehydrogenase with schistocytes on peripheral smear", "Presence of hemosiderin-laden macrophages in BAL fluid", "Concurrent acute kidney injury with proteinuria", "Elevated plasma-free hemoglobin with decreased haptoglobin", "Refractory thrombocytopenia despite platelet transfusions"], "answer": "E", "answer_index": 4, "explanation": "Transplant-associated thrombotic microangiopathy (TA-TMA) characteristically shows refractory thrombocytopenia that fails to increment appropriately with platelet transfusions due to ongoing platelet consumption in microthrombi. While elevated LDH, schistocytes, and decreased haptoglobin occur in both TA-TMA and other hemolytic processes, and AKI can occur in multiple post-transplant complications, the specific finding of platelet refractoriness distinguishes TA-TMA. Hemosiderin-laden macrophages simply confirm alveolar hemorrhage without indicating etiology. Idiopathic pneumonia syndrome does not cause platelet refractoriness.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is identifying the finding that most strongly supports diffuse alveolar hemorrhage (DAH) due to transplant-associated thrombotic microangiopathy (TA-TMA) rather than idiopathic pneumonia syndrome (IPS) in a post-allogeneic HSCT patient. Key stem clues driving a unique best answer: day +14 post-HSCT, fever, hypoxemia, diffuse infiltrates, hemorrhagic BAL with progressively bloodier aliquots, diffuse alveolar damage (DAD) on biopsy, negative galactomannan/beta-D-glucan/viral panel, and therapeutic tacrolimus levels—suggesting non-infectious pulmonary complication, with tacrolimus as a TA-TMA risk factor. These support distinguishing TA-TMA (with systemic microangiopathy) from IPS (idiopathic lung injury without TMA). Keyed answer E (refractory thrombocytopenia despite transfusions) fits due to platelet consumption in microthrombi, unique to TA-TMA over IPS. Alternatives: A (elevated LDH with schistocytes) indicates hemolysis but occurs in other processes; B (hemosiderin-laden macrophages) confirms DAH non-specifically; C (AKI with proteinuria) overlaps with multiple post-HSCT complications; D (elevated free hemoglobin/decreased haptoglobin) suggests hemolysis but not TMA-specific. Main logical issues: none; stem allows discrimination of E as most specific. Main medical accuracy issues: none; aligns with guidelines on TA-TMA diagnostics (e.g., schistocytes, LDH, refractory thrombocytopenia) and IPS exclusion of systemic TMA. Minimal fix: none needed.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is identifying the finding that most strongly supports diffuse alveolar hemorrhage (DAH) due to transplant-associated thrombotic microangiopathy (TA-TMA) rather than idiopathic pneumonia syndrome (IPS) in a post-allogeneic HSCT patient. Key stem clues driving a unique best answer: day +14 post-HSCT, fever, hypoxemia, diffuse infiltrates, hemorrhagic BAL with progressively bloodier aliquots, diffuse alveolar damage (DAD) on biopsy, negative galactomannan/beta-D-glucan/viral panel, and therapeutic tacrolimus levels—suggesting non-infectious pulmonary complication, with tacrolimus as a TA-TMA risk factor. These support distinguishing TA-TMA (with systemic microangiopathy) from IPS (idiopathic lung injury without TMA). Keyed answer E (refractory thrombocytopenia despite transfusions) fits due to platelet consumption in microthrombi, unique to TA-TMA over IPS. Alternatives: A (elevated LDH with schistocytes) indicates hemolysis but occurs in other processes; B (hemosiderin-laden macrophages) confirms DAH non-specifically; C (AKI with proteinuria) overlaps with multiple post-HSCT complications; D (elevated free hemoglobin/decreased haptoglobin) suggests hemolysis but not TMA-specific. Main logical issues: none; stem allows discrimination of E as most specific. Main medical accuracy issues: none; aligns with guidelines on TA-TMA diagnostics (e.g., schistocytes, LDH, refractory thrombocytopenia) and IPS exclusion of systemic TMA. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-005", "question": "A 3-year-old girl presents with acute onset right-sided weakness and slurred speech. CT head is negative for hemorrhage. MRI reveals acute left middle cerebral artery territory infarction. Echocardiogram shows no structural abnormalities or vegetations. Hypercoagulability workup including protein C, protein S, antithrombin III, factor V Leiden, and prothrombin gene mutation are normal. Hemoglobin electrophoresis is normal. She had chickenpox 6 weeks ago. Cerebral angiography shows focal stenosis of the left distal internal carotid artery with a \"beaded\" appearance. Which of the following is the most appropriate long-term management?", "options": ["Lifelong warfarin anticoagulation", "Aspirin therapy for 2 years with serial vascular imaging", "Immediate surgical bypass of the stenotic segment", "High-dose intravenous immunoglobulin monthly", "Indefinite dual antiplatelet therapy with aspirin and clopidogrel"], "answer": "B", "answer_index": 1, "explanation": "This presentation is classic for post-varicella arteriopathy (transient cerebral arteriopathy), which causes focal stenosis of large intracranial arteries following VZV infection. The condition is typically monophasic and self-limiting, with arterial changes stabilizing or improving over 6-24 months. Current guidelines recommend aspirin therapy for approximately 2 years with serial vascular imaging to monitor for progression or resolution. Anticoagulation is not superior to antiplatelet therapy and carries higher bleeding risk. Surgical bypass is not indicated for this typically self-resolving condition. IVIG has no established role in post-varicella arteriopathy.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute left MCA infarction in a 3-year-old with recent chickenpox (6 weeks prior), focal left distal ICA stenosis with 'beaded' appearance on angiography, and negative workups for structural heart issues, hypercoagulability, and hemoglobinopathies. These point to post-varicella arteriopathy (transient cerebral arteriopathy), a monophasic, self-limiting condition stabilizing over 6-24 months. The question asks for most appropriate long-term management. Keyed answer B (aspirin for 2 years with serial imaging) fits guidelines, assuming standard pediatric stroke protocols; it aligns with antiplatelet therapy to prevent recurrence while monitoring resolution. Alternatives: A (lifelong warfarin) inferior due to bleeding risk without superiority; C (surgical bypass) unnecessary for self-resolving stenosis; D (monthly IVIG) lacks evidence; E (indefinite dual antiplatelet) excessive duration and intensity. No main logical issues; stem allows discrimination of one best option without contradictions or underspecification. No main medical accuracy issues; consistent with current AHA/ASA guidelines for childhood arterial ischemic stroke post-VZV, emphasizing aspirin and imaging follow-up. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute left MCA infarction in a 3-year-old with recent chickenpox (6 weeks prior), focal left distal ICA stenosis with 'beaded' appearance on angiography, and negative workups for structural heart issues, hypercoagulability, and hemoglobinopathies. These point to post-varicella arteriopathy (transient cerebral arteriopathy), a monophasic, self-limiting condition stabilizing over 6-24 months. The question asks for most appropriate long-term management. Keyed answer B (aspirin for 2 years with serial imaging) fits guidelines, assuming standard pediatric stroke protocols; it aligns with antiplatelet therapy to prevent recurrence while monitoring resolution. Alternatives: A (lifelong warfarin) inferior due to bleeding risk without superiority; C (surgical bypass) unnecessary for self-resolving stenosis; D (monthly IVIG) lacks evidence; E (indefinite dual antiplatelet) excessive duration and intensity. No main logical issues; stem allows discrimination of one best option without contradictions or underspecification. No main medical accuracy issues; consistent with current AHA/ASA guidelines for childhood arterial ischemic stroke post-VZV, emphasizing aspirin and imaging follow-up. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-006", "question": "A 62-year-old man with small cell lung cancer develops progressive proximal weakness over 3 months. He has difficulty rising from chairs and climbing stairs. Examination reveals proximal muscle weakness (3/5), preserved reflexes, and no sensory deficits. CK is 4,200 U/L. EMG shows myopathic changes with fibrillation potentials. Muscle biopsy reveals necrotic and regenerating fibers with minimal inflammatory infiltrate. Testing for anti-Jo-1, anti-Mi-2, anti-SRP, and anti-MDA5 antibodies is negative. Which antibody is most likely to be positive in this patient?", "options": ["Anti-HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase)", "Anti-TIF1-gamma (transcription intermediary factor 1-gamma)", "Anti-NXP-2 (nuclear matrix protein 2)", "Anti-SAE (small ubiquitin-like modifier activating enzyme)", "Anti-HMGCR antibodies with concurrent anti-SRP positivity"], "answer": "B", "answer_index": 1, "explanation": "Anti-TIF1-gamma antibodies are strongly associated with malignancy-associated dermatomyositis/inflammatory myopathy, particularly in adults over 40 with underlying cancer. Small cell lung cancer is a known associated malignancy. The biopsy showing necrotizing features with minimal inflammation is consistent with immune-mediated necrotizing myopathy, which can occur with TIF1-gamma positivity in cancer-associated cases. Anti-HMGCR is associated with statin exposure and necrotizing myopathy but not specifically with malignancy. Anti-NXP-2 is associated with calcinosis and juvenile dermatomyositis. Anti-SAE is associated with dermatomyositis with systemic features but lower malignancy risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 62-year-old with small cell lung cancer, progressive proximal weakness, high CK (4200 U/L), myopathic EMG with fibrillations, necrotizing biopsy with minimal inflammation, negative anti-Jo-1/Mi-2/SRP/MDA5; these drive toward malignancy-associated myopathy, favoring anti-TIF1-gamma due to strong cancer link in older adults. Main logical issues: none; stem provides sufficient discriminating details (cancer type, biopsy features, negative antibodies) to identify unique best without contradictions or underspecification. Main medical accuracy issues: minor nuance—presentation lacks classic dermatomyositis rash, yet anti-TIF1-gamma is accurately associated with cancer-associated inflammatory myopathy, including necrotizing variants per current literature (e.g., strong malignancy risk >50% in positives); biopsy fits immune-mediated necrotizing myopathy in such contexts, consistent with guidelines. Alternatives: A worse as no statin exposure, not malignancy-specific; C less defensible (weaker cancer link, more juvenile/calcifying); D lower malignancy association; E invalid (SRP negative per stem). Clinical problem: most likely antibody in cancer patient with necrotizing myopathy. Implied diagnosis: paraneoplastic inflammatory myopathy. Keyed B fits without undue assumptions. Minimal fix: none needed, though adding 'absence of rash' explicitly could clarify non-DM presentation but isn't required for validity.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 62-year-old with small cell lung cancer, progressive proximal weakness, high CK (4200 U/L), myopathic EMG with fibrillations, necrotizing biopsy with minimal inflammation, negative anti-Jo-1/Mi-2/SRP/MDA5; these drive toward malignancy-associated myopathy, favoring anti-TIF1-gamma due to strong cancer link in older adults. Main logical issues: none; stem provides sufficient discriminating details (cancer type, biopsy features, negative antibodies) to identify unique best without contradictions or underspecification. Main medical accuracy issues: minor nuance—presentation lacks classic dermatomyositis rash, yet anti-TIF1-gamma is accurately associated with cancer-associated inflammatory myopathy, including necrotizing variants per current literature (e.g., strong malignancy risk >50% in positives); biopsy fits immune-mediated necrotizing myopathy in such contexts, consistent with guidelines. Alternatives: A worse as no statin exposure, not malignancy-specific; C less defensible (weaker cancer link, more juvenile/calcifying); D lower malignancy association; E invalid (SRP negative per stem). Clinical problem: most likely antibody in cancer patient with necrotizing myopathy. Implied diagnosis: paraneoplastic inflammatory myopathy. Keyed B fits without undue assumptions. Minimal fix: none needed, though adding 'absence of rash' explicitly could clarify non-DM presentation but isn't required for validity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-007", "question": "A 28-year-old woman at 32 weeks gestation presents with severe headache, visual changes, and right upper quadrant pain. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 62,000/μL, AST 342 U/L, ALT 298 U/L, LDH 890 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. Urinalysis shows 3+ protein. She receives magnesium sulfate and labetalol. Despite delivery 6 hours later, her platelet count drops to 28,000/μL and creatinine rises to 3.2 mg/dL over the next 48 hours. ADAMTS13 activity returns at 68%. Which of the following is the most appropriate next step in management?", "options": ["Initiate therapeutic plasma exchange", "Administer eculizumab", "Begin rituximab infusion", "Transfuse platelets to maintain count above 50,000/μL", "Continue supportive care with expectant management"], "answer": "B", "answer_index": 1, "explanation": "This patient has pregnancy-associated atypical hemolytic uremic syndrome (aHUS), evidenced by persistent/worsening microangiopathic hemolytic anemia and renal failure after delivery with ADAMTS13 activity >10% (ruling out TTP). Complement-mediated aHUS can be triggered by pregnancy and does not resolve with delivery alone. Eculizumab, a C5 complement inhibitor, is the treatment of choice for aHUS. Plasma exchange is first-line for TTP (ADAMTS13 <10%) but less effective in aHUS. Rituximab targets B cells and is used for autoimmune TTP. Platelet transfusion is relatively contraindicated in TMA. Expectant management risks progressive renal failure.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include persistent worsening thrombocytopenia (to 28,000/μL) and renal failure (creatinine to 3.2 mg/dL) post-delivery despite preeclampsia management, ADAMTS13 activity 68% (>10%, ruling out TTP), schistocytes, hemolysis (elevated LDH), and initial presentation mimicking HELLP but not resolving with delivery. These point to pregnancy-associated atypical hemolytic uremic syndrome (aHUS), a complement-mediated thrombotic microangiopathy. Main logical issue(s): none; the stem provides sufficient details to discriminate a single best option without contradictions or underspecification. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., Kidney Disease: Improving Global Outcomes) where eculizumab is first-line for aHUS, ADAMTS13 >10% excludes TTP, and plasma exchange is less effective for aHUS. Platelet transfusion is contraindicated in TMAs due to thrombosis risk. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include persistent worsening thrombocytopenia (to 28,000/μL) and renal failure (creatinine to 3.2 mg/dL) post-delivery despite preeclampsia management, ADAMTS13 activity 68% (>10%, ruling out TTP), schistocytes, hemolysis (elevated LDH), and initial presentation mimicking HELLP but not resolving with delivery. These point to pregnancy-associated atypical hemolytic uremic syndrome (aHUS), a complement-mediated thrombotic microangiopathy. Main logical issue(s): none; the stem provides sufficient details to discriminate a single best option without contradictions or underspecification. Main medical accuracy issue(s): none; aligns with current guidelines (e.g., Kidney Disease: Improving Global Outcomes) where eculizumab is first-line for aHUS, ADAMTS13 >10% excludes TTP, and plasma exchange is less effective for aHUS. Platelet transfusion is contraindicated in TMAs due to thrombosis risk. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-008", "question": "A 14-year-old boy with no significant medical history presents after a witnessed generalized tonic-clonic seizure lasting 2 minutes with spontaneous termination. He reports a 3-month history of early morning myoclonic jerks causing him to drop objects, which he attributed to clumsiness. EEG shows 4-6 Hz generalized polyspike-and-wave discharges with photosensitivity. MRI brain is normal. His father had similar episodes as a teenager that resolved. Which of the following medications should be specifically avoided in this patient?", "options": ["Levetiracetam", "Valproic acid", "Lamotrigine", "Carbamazepine", "Topiramate"], "answer": "D", "answer_index": 3, "explanation": "This patient has juvenile myoclonic epilepsy (JME), characterized by myoclonic jerks (especially morning), generalized tonic-clonic seizures, photosensitivity, and generalized polyspike-and-wave on EEG. Carbamazepine and other sodium channel blockers (phenytoin, oxcarbazepine) can paradoxically worsen myoclonic and absence seizures in genetic generalized epilepsies like JME by enhancing thalamocortical synchronization. Valproic acid is highly effective but avoided in women of childbearing potential due to teratogenicity. Levetiracetam and lamotrigine are appropriate alternatives. Topiramate has broad-spectrum efficacy including in JME.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include 14-year-old boy with morning myoclonic jerks, witnessed generalized tonic-clonic seizure, EEG showing 4-6 Hz generalized polyspike-and-wave discharges with photosensitivity, normal brain MRI, and paternal history of similar episodes resolving in teenage years—these strongly indicate juvenile myoclonic epilepsy (JME). The question asks for the medication to specifically avoid, and D (Carbamazepine) fits as sodium channel blockers like it can exacerbate myoclonic and absence seizures in genetic generalized epilepsies such as JME. Alternatives are inferior: A (Levetiracetam) is appropriate first-line; B (Valproic acid) is highly effective for JME in males; C (Lamotrigine) is a suitable alternative though it may rarely worsen myoclonus; E (Topiramate) has broad-spectrum efficacy including JME. Main logical issue(s): None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current epilepsy guidelines (e.g., ILAE) that contraindicate carbamazepine in JME due to risk of seizure aggravation, while other options are recommended or acceptable. Minimal fix: No edit necessary, but to enhance precision, add 'due to risk of worsening myoclonic seizures' to the rationale for emphasis.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include 14-year-old boy with morning myoclonic jerks, witnessed generalized tonic-clonic seizure, EEG showing 4-6 Hz generalized polyspike-and-wave discharges with photosensitivity, normal brain MRI, and paternal history of similar episodes resolving in teenage years—these strongly indicate juvenile myoclonic epilepsy (JME). The question asks for the medication to specifically avoid, and D (Carbamazepine) fits as sodium channel blockers like it can exacerbate myoclonic and absence seizures in genetic generalized epilepsies such as JME. Alternatives are inferior: A (Levetiracetam) is appropriate first-line; B (Valproic acid) is highly effective for JME in males; C (Lamotrigine) is a suitable alternative though it may rarely worsen myoclonus; E (Topiramate) has broad-spectrum efficacy including JME. Main logical issue(s): None; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current epilepsy guidelines (e.g., ILAE) that contraindicate carbamazepine in JME due to risk of seizure aggravation, while other options are recommended or acceptable. Minimal fix: No edit necessary, but to enhance precision, add 'due to risk of worsening myoclonic seizures' to the rationale for emphasis.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-009", "question": "A 55-year-old man is admitted to the ICU with septic shock secondary to necrotizing pancreatitis. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, his MAP remains 58 mmHg. Vasopressin 0.04 units/min is added. Central venous oxygen saturation is 58%, lactate is 6.2 mmol/L, and cardiac index by thermodilution is 2.0 L/min/m². Echocardiogram shows hyperdynamic left ventricle with LVEF 70% and small, underfilled chambers. Which of the following is the most appropriate next intervention?", "options": ["Add dobutamine for inotropic support", "Administer additional crystalloid bolus", "Initiate phenylephrine infusion", "Add epinephrine as third vasopressor", "Begin hydrocortisone 50 mg IV every 6 hours"], "answer": "B", "answer_index": 1, "explanation": "Despite initial resuscitation, the echocardiographic findings of hyperdynamic LV with small, underfilled chambers indicate persistent hypovolemia. The low ScvO2 (58%) and elevated lactate suggest inadequate oxygen delivery. In the setting of distributive shock with evidence of preload deficiency, additional volume resuscitation is indicated before adding further vasopressors. Dobutamine would be inappropriate given the already hyperdynamic state. Phenylephrine causes pure vasoconstriction without inotropy and may worsen cardiac output. Epinephrine could be considered after optimizing preload. Hydrocortisone is indicated for refractory shock but addressing hypovolemia takes priority.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (secondary: leading to M). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: Septic shock from necrotizing pancreatitis, claimed 'adequate' fluid resuscitation with norepinephrine and added vasopressin, persistent MAP 58 mmHg, low ScvO2 (58%), elevated lactate (6.2 mmol/L), low cardiac index (2.0 L/min/m²), echocardiogram showing hyperdynamic LV (LVEF 70%) with small, underfilled chambers. Main logical issue(s): Internal contradiction between 'adequate fluid resuscitation' implying sufficient volume status and echocardiographic evidence of small, underfilled chambers indicating persistent hypovolemia, rendering the item incoherent and unsolvable without ignoring part of the stem; this also leads to multiple defensible answers (B based on echo vs. E or D if trusting 'adequate' as volume optimization complete). Main medical accuracy issue(s): Intended teaching point aligns with Surviving Sepsis guidelines emphasizing preload optimization in septic shock with signs of hypovolemia before escalating vasopressors or adding steroids, but the contradiction creates a clinically unrealistic scenario where 'adequate' resuscitation coexists with objective underfilling, potentially misleading learners on volume assessment. Minimal fix: Revise stem to 'initial fluid resuscitation' instead of 'adequate' to eliminate contradiction and unambiguously support B as unique best answer.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (secondary: leading to M). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: Septic shock from necrotizing pancreatitis, claimed 'adequate' fluid resuscitation with norepinephrine and added vasopressin, persistent MAP 58 mmHg, low ScvO2 (58%), elevated lactate (6.2 mmol/L), low cardiac index (2.0 L/min/m²), echocardiogram showing hyperdynamic LV (LVEF 70%) with small, underfilled chambers. Main logical issue(s): Internal contradiction between 'adequate fluid resuscitation' implying sufficient volume status and echocardiographic evidence of small, underfilled chambers indicating persistent hypovolemia, rendering the item incoherent and unsolvable without ignoring part of the stem; this also leads to multiple defensible answers (B based on echo vs. E or D if trusting 'adequate' as volume optimization complete). Main medical accuracy issue(s): Intended teaching point aligns with Surviving Sepsis guidelines emphasizing preload optimization in septic shock with signs of hypovolemia before escalating vasopressors or adding steroids, but the contradiction creates a clinically unrealistic scenario where 'adequate' resuscitation coexists with objective underfilling, potentially misleading learners on volume assessment. Minimal fix: Revise stem to 'initial fluid resuscitation' instead of 'adequate' to eliminate contradiction and unambiguously support B as unique best answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-010", "question": "A 7-year-old boy presents with 2 weeks of progressive gait instability and tremor. Examination reveals opsoclonus (chaotic, multidirectional saccadic eye movements), myoclonus, and truncal ataxia. MRI brain and spine are normal. CSF shows mild lymphocytic pleocytosis. CT chest/abdomen/pelvis reveals a paraspinal mass. Urine catecholamines are elevated. Tumor resection is planned. Which of the following additional findings would indicate the WORST long-term neurodevelopmental prognosis despite tumor treatment?", "options": ["Presence of anti-Hu antibodies in serum", "CSF oligoclonal bands with elevated IgG index", "Age less than 3 years at symptom onset", "Tumor histology showing neuroblastoma with MYCN amplification", "Delayed initiation of immunotherapy beyond 4 weeks from diagnosis"], "answer": "C", "answer_index": 2, "explanation": "Opsoclonus-myoclonus-ataxia syndrome (OMS) associated with neuroblastoma has variable neurodevelopmental outcomes. Younger age at onset (particularly <3 years) is paradoxically associated with worse long-term cognitive and behavioral outcomes, likely due to the impact of neuroinflammation on the developing brain during critical periods. While MYCN amplification indicates aggressive tumor biology, it does not correlate with neurological outcomes. Anti-Hu antibodies are rare in pediatric OMS. CSF inflammatory markers and treatment delays affect outcomes but age remains the strongest predictor of neurodevelopmental sequelae.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: 7-year-old boy with 2 weeks of gait instability, tremor, opsoclonus, myoclonus, truncal ataxia; normal MRI brain/spine; mild CSF lymphocytic pleocytosis; paraspinal mass on CT; elevated urine catecholamines—consistent with neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome (OMS). The question asks for additional finding indicating worst long-term neurodevelopmental prognosis despite tumor treatment.\\nMain logical issue(s): Internal contradiction (C)—option C ('Age less than 3 years at symptom onset') directly contradicts the vignette's stated patient age of 7 years, making it impossible as an 'additional finding.' This incoherence undermines defensibility of any answer, as C cannot apply without rewriting the stem, potentially leading to ambiguity in selecting a unique best option.\\nMain medical accuracy issue(s): Minor issues only; the intended teaching point aligns with established knowledge that younger age (<3 years) at OMS onset in neuroblastoma predicts worse neurodevelopmental outcomes due to neuroinflammation during brain development. Other options (anti-Hu antibodies, CSF markers, MYCN amplification, treatment delay) are accurately portrayed as less predictive or rare/irrelevant in pediatrics, per current guidelines and literature.\\nMinimal fix: Rephrase the question stem to 'Which of the following findings in a patient with this condition would indicate the WORST long-term neurodevelopmental prognosis despite tumor treatment?' to decouple options from the specific vignette's age, eliminating the contradiction.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: 7-year-old boy with 2 weeks of gait instability, tremor, opsoclonus, myoclonus, truncal ataxia; normal MRI brain/spine; mild CSF lymphocytic pleocytosis; paraspinal mass on CT; elevated urine catecholamines—consistent with neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome (OMS). The question asks for additional finding indicating worst long-term neurodevelopmental prognosis despite tumor treatment.\nMain logical issue(s): Internal contradiction (C)—option C ('Age less than 3 years at symptom onset') directly contradicts the vignette's stated patient age of 7 years, making it impossible as an 'additional finding.' This incoherence undermines defensibility of any answer, as C cannot apply without rewriting the stem, potentially leading to ambiguity in selecting a unique best option.\nMain medical accuracy issue(s): Minor issues only; the intended teaching point aligns with established knowledge that younger age (<3 years) at OMS onset in neuroblastoma predicts worse neurodevelopmental outcomes due to neuroinflammation during brain development. Other options (anti-Hu antibodies, CSF markers, MYCN amplification, treatment delay) are accurately portrayed as less predictive or rare/irrelevant in pediatrics, per current guidelines and literature.\nMinimal fix: Rephrase the question stem to 'Which of the following findings in a patient with this condition would indicate the WORST long-term neurodevelopmental prognosis despite tumor treatment?' to decouple options from the specific vignette's age, eliminating the contradiction.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 4}]